NordMason major shareholder iNtRON Biotech cuts stake to 17.76% from 30.78% after CB expiry

Bitget2026/10/06 07:18

iNtRON Biotechnology cut its stake in NordMason to 801,467 shares, or 17.76%, from 1,363,264 shares, or 30.78%. Change dated Oct. 1, 2026, driven by expiry of conversion rights on the company’s 1st unsecured private placement convertible bond. Disclosure also flagged ongoing talks on bond repayment following a debtor default by the issuer. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NordMason Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261006000299), on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.